Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MGAM | O43451 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SI | P14410 | 1/20 | 0.32 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6538686 | 0.87 | HDAC6 (0.37) | ALDH1A1SMN1; SMN2HDAC6CYP1A2CA14 | |
| SCHEMBL19187948 | 0.87 | NFKB1 (0.36) | ALDH1A1SMN1; SMN2HDAC6CYP1A2CA14 | |
| SCHEMBL23624143 | 0.85 | KMT2A (0.40) | ALDH1A1HDAC6CA14HDAC1HDAC2 | |
| SCHEMBL376299 | 0.85 | F2 (0.38) | ALDH1A1SMN1; SMN2HDAC6CYP1A2CA14 | |
| SCHEMBL6538656 | 0.85 | CA14 (0.39) | ALDH1A1SMN1; SMN2HDAC6CYP1A2CA14 | |
| SCHEMBL15312506 | 0.82 | SMN1; SMN2 (0.38) | ALDH1A1SMN1; SMN2HDAC6CYP1A2CA14 | |
| SCHEMBL6538877 | 0.82 | CA14 (0.39) | ALDH1A1HDAC6CA14HDAC1HDAC2 | |
| SCHEMBL1272960 | 0.82 | CA14 (0.49) | ALDH1A1SMN1; SMN2HDAC6CYP1A2CA14 | |
| SCHEMBL20045144 | 0.82 | CA14 (0.39) | ALDH1A1SMN1; SMN2HDAC6CYP1A2CA14 | |
| SCHEMBL15942130 | 0.82 | CA14 (0.38) | ALDH1A1HDAC6CA14HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680335-A1 | UREA DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | Ventus Therapeutics U.S., Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4680336-A1 | AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | Ventus Therapeutics U.S., Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20260007684-A1 | AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | VENTUS THERAPEUTICS U S INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-20260008768-A1 | UREA DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | VENTUS THERAPEUTICS U S INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-12479837-B2 | Reversible DPP1 inhibitors and uses thereof | INSMED INCORPORATED (US) | 2025-11-25 | — | — | US | disclosed |
| EP-4646265-A1 | NOVEL, REVERSIBLE DPP1 INHIBITORS AND USES THEREOF | Insmed Incorporated (US) | 2025-11-12 | — | — | EP | disclosed |
| US-20250223284-A1 | REVERSIBLE DPP1 INHIBITORS AND USES THEREOF | INSMED INCORPORATED | 2025-07-10 | — | — | US | disclosed |
| WO-2024196788-A1 | AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. (US) | 2024-09-26 | — | — | WO | disclosed |
| WO-2024196786-A1 | UREA DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. (US) | 2024-09-26 | — | — | WO | disclosed |
| CN-113795491-B | Bridged ring-3, 4-dihydro-pyrido [1,2-a ] pyrazine-1, 8-dione compounds and pharmaceutical uses thereof | 上海拓界生物医药科技有限公司 | 2024-09-03 | — | — | CN | disclosed |
| US-20120165306-A1 | PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-06-28 | — | — | US | disclosed |
| US-20120157433-A1 | Heteroaryl Compounds as Kinase Inhibitors | PFISTER KEITH B (US) | 2012-06-21 | — | — | US | disclosed |
| US-20110130380-A1 | Heteroaryl Kinase Inhibitors | NOVARTIS AG (CH) | 2011-06-02 | — | — | US | disclosed |
| WO-2011026911-A1 | BIPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2011-03-10 | — | — | WO | disclosed |
| WO-2011026917-A1 | HETEROARYL COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-03-10 | — | — | WO | disclosed |
| WO-2011026904-A1 | PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2011-03-10 | — | — | WO | disclosed |
| US-6812235-B2 | 2-ACYLAMINO- BETA -ALANINE DERIVATIVES AND A PHARMACEUTICALLY ACCEPTABLE SALT, USEFUL AS FIBRINOGEN RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-02 | — | — | US | disclosed |
| US-20030018193-A1 | Beta-alanine derivatives and their use as receptor anatgonists | ASTELLAS PHARMA INC. (JP) | 2003-01-23 | — | — | US | disclosed |
| EP-1255748-A1 | BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001060813-A1 | BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008768-A1 | UREA DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | NOD1, NLRP3, NOD2 | ALDH1A1 1340/4885SMN1; SMN2 3180/4885HDAC6 630/4885 |
| US-20250223284-A1 | REVERSIBLE DPP1 INHIBITORS AND USES THEREOF | DPP4, DPP7, DPP9 | ALDH1A1 125/4885SMN1; SMN2 880/4885HDAC6 578/4885 |
| US-20120157433-A1 | Heteroaryl Compounds as Kinase Inhibitors | CDK2, CDK1, CDK6 | ALDH1A1 1961/4885SMN1; SMN2 2126/4885HDAC6 436/4885 |
| US-20110130380-A1 | Heteroaryl Kinase Inhibitors | CDK2, CDK1, CDKL1 | ALDH1A1 1763/4885SMN1; SMN2 2172/4885HDAC6 482/4885 |
| US-20030018193-A1 | Beta-alanine derivatives and their use as receptor anatgonists | ARRB1, ADRB1, GLRB | ALDH1A1 578/4885SMN1; SMN2 2439/4885HDAC6 3137/4885 |
| US-12479837-B2 | Reversible DPP1 inhibitors and uses thereof | DPP4, DPP7, DPP9 | ALDH1A1 125/4885SMN1; SMN2 880/4885HDAC6 578/4885 |
| US-20120165306-A1 | PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | CDK4, CDK1, CCNI | ALDH1A1 1528/4885SMN1; SMN2 2827/4885HDAC6 316/4885 |
| US-20260007684-A1 | AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | NOD1, NLRP3, NOD2 | ALDH1A1 1304/4885SMN1; SMN2 3274/4885HDAC6 346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.